Theravance Biopharma confirmed it will wind down research and development activities and cut roughly half its workforce after its norepinephrine reuptake inhibitor failed a Phase III study in multiple system atrophy. The company will retain commercial and partnered assets while halting further early‑stage programs. Management framed the move as a pivot to preserve cash and maximize value from approved and partnered products, but investors responded with a sharp pullback in the stock. The decision underlines the binary risk profile of late‑stage failures for small biotechs with narrow pipelines and highlights the operational impact of repeated pivotal misses.